يعرض 1 - 20 نتائج من 208 نتيجة بحث عن '"Baccara Dinet, Marie"', وقت الاستعلام: 0.62s تنقيح النتائج
  1. 1
  2. 2
    Academic Journal
  3. 3
  4. 4
    Academic Journal
  5. 5
    Academic Journal
  6. 6
  7. 7
    Academic Journal

    المصدر: 0195-668X.

    Relation: http://urn.nb.no/URN:NBN:no-88409; Szarek, Michael Bittner, Vera A. Aylward, Philip Baccara-Dinet, Marie T. Bhatt, Deepak L. Diaz, Rafael Fras, Zlatko Goodman, Shaun G. Halvorsen, Sigrun Harrington, Robert A Jukema, J Wouter Moriarty, Patrick M. Pordy, Robert Ray, Kausik K Sinnaeve, Peter Tsimikas, Sotirios Vogel, Robert White, Harvey D. Zahger, Doron Zeiher, Andreas M. Steg, Philippe Gabriel Schwartz, Gregory G. . Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. European Heart Journal. 2020; http://hdl.handle.net/10852/85747; 1898301; info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European Heart Journal&rft.volume=&rft.spage=&rft.date=2020; European Heart Journal; 41; 44; 4245; 4255; https://doi.org/10.1093/eurheartj/ehaa649; URN:NBN:no-88409; Fulltext https://www.duo.uio.no/bitstream/handle/10852/85747/2/Szarek%2Bet%2Bal.pdf

  8. 8
    Academic Journal
  9. 9
    Academic Journal
  10. 10
    Academic Journal

    المساهمون: HUS Heart and Lung Center, Clinicum, CAMM - Research Program for Clinical and Molecular Metabolism, Research Programs Unit, University of Helsinki

    وصف الملف: application/pdf

    Relation: The authors would like to thank study individuals and investigators, and the following persons from sponsors for their contributions to data collection and analysis, assistance with statistical analysis, or critical review of the manuscript: Regeneron: Eva-Lynne Greene, Carol Hudson, Rita Samuel, Desmond Thompson; Sanofi: Corinne Hanotin, Michael Howard, L. Veronica Lee, Guillaume Lecorps, Laurence Merlet, Christelle Lorenzato, and Jonas Mandel. This analysis was funded by Sanofi and Regeneron Pharmaceuticals, Inc. Medical writing support was provided by Rachel Wright, PhD, and Susanne Ulm, PhD, of Prime (Knutsford, UK), funded by Sanofi and Regeneron Pharmaceuticals Inc according to Good Publication Practice guidelines (http://annals.org/aim/article/2424869/goodpublic ation-practice-communi cating-company-sponsored-medical-research-gpp3). The Sponsor was involved in the study design, collection, analysis, and interpretation of data, as well as data checking of information provided in the manuscript. The authors had unrestricted access to data, were responsible for all content and editorial decisions, and received no honoraria related to the development of this publication.; Robinson , J G , Farnier , M , Kastelein , J J P , Roth , E M , Taskinen , M-R , Colhoun , H M , Brunet , A , DiCioccio , A T , Lecorps , G , Pordy , R , Baccara-Dinet , M T & Cannon , C P 2019 , ' Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses ' , Journal of Clinical Lipidology , vol. 13 , no. 6 , pp. 979-988 . https://doi.org/10.1016/j.jacl.2019.10.004; ORCID: /0000-0002-6229-3588/work/90757005; http://hdl.handle.net/10138/310405; 3d35c2bb-8135-4987-aa8e-a5a27bada2ff; 000504803700016

  11. 11
  12. 12
    Academic Journal
  13. 13
    Academic Journal
  14. 14
  15. 15
    Academic Journal
  16. 16
    Academic Journal
  17. 17
    Academic Journal
  18. 18
    Academic Journal
  19. 19
  20. 20